Wenling Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3155077/publications.pdf

Version: 2024-02-01

48 papers	2,501 citations	201674 27 h-index	214800 47 g-index
49 all docs	49 docs citations	49 times ranked	2631 citing authors

#	Article	IF	Citations
1	Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy. Genes and Diseases, 2022, 9, 981-999.	3.4	22
2	Long non-coding RNAs are involved in alternative splicing and promote cancer progression. British Journal of Cancer, 2022, 126, 1113-1124.	6.4	53
3	Mitochondrial DNA in NLRP3 inflammasome activation. International Immunopharmacology, 2022, 108, 108719.	3.8	35
4	Extrachromosomal Circular DNA: A New Target in Cancer. Frontiers in Oncology, 2022, 12, 814504.	2.8	6
5	The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment. Gene, 2022, 834, 146564.	2.2	3
6	circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma. Oncogene, 2021, 40, 307-321.	5.9	51
7	Mitochondriaâ€associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. Synapse, 2021, 75, e22196.	1.2	8
8	Identification of potential biomarkers associated with immune infiltration in the esophageal carcinoma tumor microenvironment. Bioscience Reports, 2021, 41, .	2.4	10
9	Research Progress of circRNAs in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 616202.	2.8	9
10	The Multifunctional Roles of Short Palate, Lung, and Nasal Epithelium Clone 1 in Regulating Airway Surface Liquid and Participating in Airway Host Defense. Journal of Interferon and Cytokine Research, 2021, 41, 139-148.	1.2	1
11	Expression of PD-L1 in EBV-associated malignancies. International Immunopharmacology, 2021, 95, 107553.	3.8	16
12	The role of B7-H3 in tumors and its potential in clinical application. International Immunopharmacology, 2021, 101, 108153.	3.8	22
13	The role of alternative splicing in human cancer progression. American Journal of Cancer Research, 2021, 11, 4642-4667.	1.4	3
14	Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells. Biochemical and Biophysical Research Communications, 2020, 522, 1063-1068.	2.1	28
15	Upregulation of cyclin D1 can act as an independent prognostic marker for longer survival time in human nasopharyngeal carcinoma. Journal of Clinical Laboratory Analysis, 2020, 34, e23298.	2.1	4
16	EBVâ€miRâ€BART12 accelerates migration and invasion in EBVâ€associated cancer cells by targeting tubulin polymerizationâ€promoting protein 1. FASEB Journal, 2020, 34, 16205-16223.	0.5	19
17	The role of HOPX in normal tissues and tumor progression. Bioscience Reports, 2020, 40, .	2.4	21
18	Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene, 2019, 38, 88-102.	5.9	67

#	Article	IF	Citations
19	APLNR is involved in ATRAâ€induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3Kâ€Aktâ€mTOR signaling. FASEB Journal, 2019, 33, 11959-11972.	0.5	19
20	Herpesvirus acts with the cytoskeleton and promotes cancer progression. Journal of Cancer, 2019, 10, 2185-2193.	2.5	31
21	Upregulation and hypomethylation of lncRNA AFAP1â€‘AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. Oncology Reports, 2019, 41, 2431-2439.	2.6	42
22	Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathwayâ€"Meditated Epithelial-Mesenchymal Transition. Pancreas, 2019, 48, 629-635.	1.1	8
23	BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell Death and Disease, 2018, 9, 432.	6.3	70
24	BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. British Journal of Cancer, 2018, 118, 233-247.	6.4	73
25	High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis. Journal of Cancer, 2018, 9, 4677-4683.	2.5	69
26	Inhibin B suppresses anoikis resistance and migration through the transforming growth factorâ€Î²2 signaling pathway in nasopharyngeal carcinoma. Cancer Science, 2018, 109, 3416-3427.	3.9	24
27	Circular RNAs in human cancer. Molecular Cancer, 2017, 16, 25.	19.2	310
28	Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens. Journal of Virology, 2017, 91, .	3.4	70
29	MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN. Oncotarget, 2017, 8, 5206-5218.	1.8	26
30	HYOU1, Regulated by LPLUNC1, Is Up-Regulated in Nasopharyngeal Carcinoma and Associated with Poor Prognosis. Journal of Cancer, 2016, 7, 367-376.	2.5	51
31	The delta high-density lipoprotein cholesterol ratio: a novel parameter for gram-negative sepsis. SpringerPlus, 2016, 5, 1044.	1.2	13
32	An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma. Tumor Biology, 2016, 37, 3683-3695.	1.8	61
33	AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumor Biology, 2016, 37, 729-737.	1.8	132
34	Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget, 2015, 6, 20404-20418.	1.8	210
35	EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC. Oncotarget, 2015, 6, 41766-41782.	1.8	96
36	Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma. Tumor Biology, 2015, 36, 675-683.	1.8	28

#	Article	IF	Citations
37	LOC401317, a p53-Regulated Long Non-Coding RNA, Inhibits Cell Proliferation and Induces Apoptosis in the Nasopharyngeal Carcinoma Cell Line HNE2. PLoS ONE, 2014, 9, e110674.	2.5	93
38	<scp>SPLUNC</scp>1 is associated with nasopharyngeal carcinoma prognosis and plays an important role in allâ€transâ€retinoic acidâ€induced growth inhibition and differentiation in nasopharyngeal cancer cells. FEBS Journal, 2014, 281, 4815-4829.	4.7	21
39	Regulation network and expression profiles of Epstein-Barr virus-encoded microRNAs and their potential target host genes in nasopharyngeal carcinomas. Science China Life Sciences, 2014, 57, 315-326.	4.9	66
40	Oxidored-nitro domain containing protein 1 (NOR1) expression suppresses slug/vimentin but not snail in nasopharyngeal carcinoma: Inhibition of EMT in vitro and in vivo in mice. Cancer Letters, 2014, 348, 109-118.	7.2	30
41	miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis, 2013, 34, 415-425.	2.8	108
42	Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. Journal of Molecular Histology, 2013, 44, 545-554.	2.2	104
43	Evaluation of the prognostic value of TGF-Î² superfamily type I receptor and TGF-Î² type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. Journal of Molecular Histology, 2012, 43, 297-306.	2.2	43
44	The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology, 2012, 138, 49-56.	2.5	65
45	microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis, 2010, 31, 559-566.	2.8	145
46	Identification of aberrant cell cycle regulation in Epstein–Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochimica Et Biophysica Sinica, 2009, 41, 414-428.	2.0	52
47	Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray. Journal of Cancer Research and Clinical Oncology, 2006, 133, 71-81.	2.5	62
48	NUCB2: roles in physiology and pathology. Journal of Physiology and Biochemistry, 0, , .	3.0	0